Domain 5 of kininogen inhibits proliferation of human colon cancer cell line (HCT-116) by interfering with G1/S in the cell cycle

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 2, 2007, Pages 403-411

  Bior, A D ^a   Pixley, R A ^a   Colman, R W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colon cancer; G1 S; HCT 116; HK D5; Kininogen

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; KININOGEN; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOBLASTOMA PROTEIN; SERINE; TRANSCRIPTION FACTOR E2F; UROKINASE RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; INCUBATION TIME; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; G1 PHASE; HUMANS; INTERPHASE; KININOGENS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; RETINOBLASTOMA PROTEIN; S PHASE;

EID: 33846442074     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02352.x     Document Type: Article

References (49)

1. Rojkjaer R, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc Assoc Am Physicians 1999; 111: 220-7.
2. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) downregulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-50.
3. Zhang JC, Claffey K, Sakthivel R, David ES, Zbigniev D, Lu F-M, McCrae KM. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can J Physiol Pharmacol 2002; 80: 85-90.
4. Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN, Powell JA, Mousa SA. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 2003; 1: 164-70.
5. Mauron T, Lammle B, Wuillemin WA. High molecular weight kininogen is cleaved by FXIa at three sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. Thromb Haemost 2000; 83: 709-14.
6. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1427-33.
7. Guo YL, Wang S, Cao DJ, Colman RW. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem 2003; 89: 622-32.
8. Semba S, Itoh N, Ito M, Harada M, Yamakawa M. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells. Clin Cancer Res 2002; 8: 1957-63.
9. Miehlke S, Yu J, Ebert M, Szokodi D, Vieth M, Kuhlisch E, Buchcik R, Schimmin W, Wehrmann U, Malfertheiner P, Ehninger G, Bayerdorffer E, Stolte M. Expression of G1 phase cyclins in human gastric cancer and gastric mucosa of first-degree relatives. Dig Dis Sci 2002; 47: 1248-56.
10. Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain: Identification of two anionic surface binding subdomains. J Biol Chem 1993; 268: 2486-92.
11. Russo P, Ottoboni C, Crippa A, Riou JF, O'Connor PM. RPR-115135, a new nonpeptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells. Int J Oncol 2001; 18: 855-62.
12. Kiess M, Gill RM, Hamel PA. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation. Cell Growth Differ 1995; 6: 1287-98.
13. Timchenko NA, Wilde M, Iakova P, Albrecht JH, Darlington GJ. E2F/p107 and E2F/p130 complexes are regulated by C/EBPalpha in 3T3-L1 adipocytes. Nucl Acids Res 1999; 27: 3621-30.
14. Xiao B, Spencer J, Clements A, Ali-Khan N, Mittnacht S, Broceno C, Burghammer M, Perrakis A, Marmorstein R, Gamblin SJ. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc Natl Acad Sci USA 2003; 100: 2363-8.
15. Classon M, Dyson N. p107 and p130: Versatile proteins with interesting pockets. Exp Cell Res 2001; 264: 135-47.
16. O'Connor RJ, Schaley JE, Feeney G, Hearing P. The p107 tumor suppressor induces stable E2F DNA binding to repress target promoters. Oncogene 2001; 20: 1882-91.
17. Stillman B. Cell cycle control of DNA replication. Science 1996; 274: 1659-64.
18. Murga C, Fukuhara S, Gutkind JS. A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. J Biol Chem 2000; 275: 12069-73.
19. Benistant C, Chapuis H, Roche S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 2000; 19: 5083-90.
20. Verdu J, Buratovich MA, Wilder EL, Birnbaum MJ. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat Cell Biol 1999; 1: 500-6.
21. Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. Clin Cancer Res 2000; 6: 193-202.
22. Zhang SY, Liu S-C, Goodrow T, Morris R, Klein-Szanto AJP. Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol Carcinog 1997; 18: 142-52.
23. Achanzar WE, Webber MM, Waalkes MP. Altered apoptotic gene expression and acquired apoptotic resistance in cadmium-transformed human prostate epithelial cells. Prostate 2002; 52: 236-44.
24. Chigbrow M, Nelson M. Inhibition of mitotic cyclin B and cdc2 kinase activity by selenomethionine in synchronized colon cancer cells. Anticancer Drugs 2001; 12: 43-50.
25. Moragoda L, Jaszewski R, Majumdar AP. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 2001; 21: 873-8.
26. Lui VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res 2002; 22: 1-11.
27. Geddert H, Heep HJ, Gabbert HE, Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer 2002; 94: 212-8.
28. Morgan DO. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 1997; 13: 261-91.
29. Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 1996; 16: 6917-25.
30. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin Jr WG. The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol 1995; 15: 742-55.
31. Hasskarl J, Butz K, Whitaker N, Ullmann A, Durst M, Hoppe-Seyler F. Differential cell cycle response of nontumorigenic and tumorigenic human papillomavirus-positive keratinocytes towards transforming growth factor-beta1. J Mol Med 2000; 78: 94-101.
32. Hanai J, Dhanabal M, Ananth Karumanchi S, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, Sukhatme VP. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002; 277: 16464-9.
33. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev 1998; 8: 28-35.
34. Gali-Muhtasib H, Bakkar N. Modulating cell cycle: Current applications and prospects for future drug development. Curr Cancer Drug Targets 2002; 2: 309-36.
35. Furukawa Y. Cell cycle control during hematopoietic cell differentiation. Hum Cell 1997; 10: 159-64.
36. Furukawa Y. Cell cycle regulation of hematopoietic stem cells. Hum Cell 1998; 11: 81-92.
37. Leezer J, Hackmiller RC, Greene RM, Pisano MM. Expression of the retinoblastoma family of tumor suppressors during murine embryonic orofacial development. Orthod Craniofac Res 2003; 6: 32-47.
38. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246: 603-8.
39. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-62.
40. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10: 699-703.
41. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8.
42. Donjerkovic D, Scott DW. Regulation of the G1 phase of the mammalian cell cycle. Cell Res 2000; 10: 1-16.
43. Wang J, Barsky LW, Shum CH, Jong A, Weinberg KI, Collins SJ, Triche TJ, Wu L. Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J Biol Chem 2002; 277: 43369-76.
44. Yoneda K, Yamamoto T, Ueta E, Osaki T. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett 1998; 133: 35-45.
45. Agami R, Bernards R. Convergence of mitogenic and DNA damage signaling in the G1 phase of the cell cycle. Cancer Lett 2002; 177: 111-8.
46. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris) 2000; 48: 190-202.
47. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol 2000; 36: 3-7.
48. Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, Dubus P, Barbacid M. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118: 493-504.
49. Katkade V, Soyombo AA, Isordia-Salas I, Bradford HN, Gaughan JP, Colman RW, Panetti TS. Domain 5 of cleaved high molecular weight kininogen inhibits endothelial cell migration through Akt. Thromb Haemost 2005; 94: 606-14.